A STUDY ON MEDICAL ADHERENCE BASED ON MORISKY SCORE IN RHEUMATOID ARTHRITIS PATIENTS IN MILITARY HOSPITAL 103
Main Article Content
Abstract
Objectives: To study the grade of treatment adherence in patients with RA according to the Morisky's scale and to analyze the relationship between the level of treatment compliance according to the Morisky's scores and some clinical and paraclinical characteristics in RA patients. Methods: A cross-sectional and descriptive study on 80 RA patients treated at Military Hospital 103. Treatment adherence was assessed according to the 8-question Morisky scale. Results: The mean of the Morisky score was 6.25/8 points. Of these, 43.8% had low compliance, 35% had medium compliance, and 21.2% had high compliance. Factors associated with poor compliance were mainly high drug costs and adverse effects, as well as low confidence in the treatment plan. Regarding disease characteristics, Morisky score was positively correlated with disease duration (adjusted B 0.269) with p=0.001, negatively correlated with DAS28-CRP (adjusted B -0.391), and number of DMARDs used (adjusted B -0.396) with all p <0.001. Conclusion: Treatment adherence in RA patients was mostly low. The main reasons for low adherence were treatment costs and adverse effects. Adherence was related to disease activity, number of DMARDs prescribed, and disease duration.
Article Details
Keywords
treatment adherence, RA, Morisky 8 questions
References
2. Tanaka E, Mannalithara A, Inoue E, Hara M, Tomatsu T, Kamatani N, et al. Efficient management of rheumatoid arthritis significantly reduces long-term functional disability. Ann Rheum Dis. 2008;67: 1153–1158. doi:10.1136/ ard.2007.072751
3. Pascual-Ramos V, Contreras-Yáñez I, Villa AR, Cabiedes J, Rull-Gabayet M. Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability. Arthritis Res Ther. 2009;11: R26. doi:10.1186/ar2620
4. Burkhart P V, Sabaté E. Adherence to long-term therapies: evidence for action. J Nursh Sch. 2003;35: 207. Available: http://www.ncbi.nlm.nih. gov/pubmed/14562485
5. Waeber B, Leonetti G, Kolloch R, McInnes GT. Compliance with aspirin or placebo in the hypertension optimal treatment (HOT) study. J Hypertens. 1999;17: 1041–1045. doi:10.1097/00004872-199917070-00022
6. Morisky DE, Ang A, Krousel‐Wood M, Ward HJ. Predictive Validity of a Medication Adherence Measure in an Outpatient Setting. J Clin Hypertens. 2008;10: 348–354. doi:10.1111/ j.1751-7176.2008.07572.x
7. Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology. 2012;51: vi5–vi9. doi:10.1093/ rheumatology/kes279
8. Gadallah MA, Boulos DNK, Dewedar S, Gebrel A, Morisky DE. Assessment of Rheumatoid Arthritis Patients’ Adherence to Treatment. Am J Med Sci. 2015;349: 151–156. doi:10.1097/MAJ.0000000000000376
9. Pombo-Suarez M, Maneiro Fernandez JR, Gomez-Reino JJ. Adherence to Treatment in Patients with Rheumatoid Arthritis from Spain. Patient Prefer Adherence. 2021;Volume 15: 111–117. doi:10.2147/PPA.S291983
10. Balsa A, García de Yébenes MJ, Carmona L. Multilevel factors predict medication adherence in rheumatoid arthritis: a 6-month cohort study. Ann Rheum Dis. 2022;81: 327–334. doi:10.1136/ annrheumdis-2021-221163